Psilocybin-assisted therapy for alcohol addiction had positive results with therapeutic gains which were maintained as much as 36 weeks later (Bogenschutz et al., 2015).
Psilocybin-assisted therapy for alcohol addiction had positive results with therapeutic gains which were maintained as much as 36 weeks later (Bogenschutz et al., 2015).
We will begin this module with a brief introduction to substance use disorders. Then, we will look at how both ketamine and classic psychedelics (primarily psilocybin) and to a lesser extent MDMA, have shown promising results for treating substance use disorders. We will look at some first-hand accounts of people who have struggled with a substance use disorder and subsequently underwent psychedelic-assisted therapy. Then, we will look at motivational enhancement therapy and how this can be used in combination with psychedelic-assisted therapy in the treatment of substance use disorders.
Upon successful completion of the module, you will be able to:
Identify which psychedelic medicines have been used for psychedelic-assisted therapy in the treatment of substance use disorders.
Describe key evidence-based literature supporting the use of psychedelic-assisted therapy in the treatment of substance use disorders.
Demonstrate a rudimentary understanding of motivational interviewing and motivational enhancement therapy and how it relates to psychedelic-assisted therapy in the treatment of substance use disorders.
Explain the importance of relapse prevention skills as an important part of the treatment of substance use disorders.